This phase I/II trial studies the side effects and the best dose of veliparib when given together with bendamustine hydrochloride and rituximab and to see how well they work in treating patients with
[interquartile range] are shown. HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, Non-alcoholic steatohepatitis; MELD, the model for end stage liver disease; CRP, C-reactive protein; AFP, a-fetop
